GC Green Cross Chickenpox Vaccine 'Varicellavax' Two-Dose Phase 3 Clinical Trial Approved in Korea
Korea Added to Ongoing Trials in Thailand and Vietnam
Direct Comparison with MSD's Varivax
GC Green Cross announced on July 2 that it has received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial protocol (IND) of its chickenpox vaccine, 'Varicellavax,' for a two-dose (2-dose) regimen.
This clinical trial is a multinational study that adds Korea to the ongoing global trials in Thailand and Vietnam. It will enroll 474 healthy children aged between 12 months and 12 years. The study aims to directly compare Varicellavax to 'Varivax,' the chickenpox vaccine from Merck (MSD) in the United States, in order to assess the immunogenicity and safety of Varicellavax.
The chickenpox vaccine market is shifting toward a two-dose regimen to reduce breakthrough infections that can occur after a single dose. Twenty-eight countries, including major nations such as the United States, Canada, and Japan, have adopted the two-dose schedule, and the World Health Organization (WHO) also recommends two doses for chickenpox prevention.
Varicellavax is a vaccine developed by GC Green Cross in 1993, based on the 'MAV/06' strain. The MAV/06 strain was listed in the WHO chickenpox vaccine guidelines in November last year. It has established the same level of reliability as the conventional Oka-based chickenpox vaccines.
GC Green Cross plans to obtain product approval for the two-dose regimen in Korea and key Southeast Asian countries by 2028, following the completion of multinational clinical trials.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jaeu Lee, Head of Development at GC Green Cross, said, "The two-dose clinical trial for Varicellavax is a key step in strengthening our vaccine portfolio's competitiveness," and added, "We will further expand its global market utilization."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.